Back

Pharmosa’s L606 enters China sites for global Phase 3 PH-ILD trial

Verifying
  • Pharmosa said Liquidia received approval to activate China sites in L606’s global Re-Spire trial.
  • China’s NMPA approved participation in the Phase 3 trial for PH-ILD.
  • Pharmosa retains L606’s China market rights and continues commercialization discussions.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Pharmosa’s L606 enters China sites for global Phase 3 PH-ILD trial - CoinPost Terminal